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Obligate intracellular coccoid parasites 
contain DNA and RNA, and 
ribosomes 
lack ATP, biosynthetic pathways 
cell wall but peptidoglycan 
absent - 
 use disulfide bonds 
non motile 
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Gram negative  
Characteristic development cycle 
•Elementary body (infectious form) 
•Reticulate body (metabolic form) 
Chlamydial Morphologies 
Elementary body 
0.25 - 0.3 µm diameter 
electron-dense nucleoid 
Released from ruptured infected cells.  
Human to human 
& bird to human. 
Reticulate Body  
Intra cytoplasmic form 0.5 - 1.0 µm     
Replication and growth. ( Inclusion body ) 
without a dense center.  
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Chlamydiaceae Family 
(species that cause disease in humans) 
Species (genus) Disease 
C. trachomatis 
2 biovars, non-LGV 
                        LGV 
Trachoma, NGU, 
MPC, PID, 
conjunctivitis, 
Infant pneumonia, 
LGV 
C. pneumoniae 
Pharyngitis, 
bronchitis, 
pneumonia 
C. psittaci Psittacosis 
4 
By: Mehri Sadeghi /                                          
Dr. M.Aslanimehr 
5 
By: Mehri Sadeghi /                                          
Dr. M.Aslanimehr 
6 
Female Sequelae 
Chlamydia can increase HIV 
transmission 3-5 fold 
Up to 15% risk of pelvic inflammatory 
disease (PID) with untreated chlamydia 
PID outcomes:  
Infertility (1 in 5) 
Ectopic pregnancy (1 in 10) 
Chronic pelvic pain (1 in 5) 
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The value of animal models 
animal models are useful and convenient, they must 
provide data about vaccination that will eventually be 
transferrableto the human situation. In the case of chlamydial 
STIs, the mouse model is the most widely used model for 
infection, pathogenesisand vaccine studies. Primary genital 
tract infections of female mice with elementary bodies of the 
mouse-adapted Chlamydia muridarum strain are enough to 
cause tubal dilatation since a consistentobservation is the 
development of hydrosalpinx shortly (1–2 days)after initial 
chlamydial infection in this model. Hydrosalpinx 
characteristically is also associated with tubal factor infertility in 
humans  making this model useful in this respect.  
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However this observation in the murine model contrasts 
with documente devidence from the guinea pig Chlamydia 
caviae model of a primary genital tract infection in which 
chronic oviduct pathology was reported in only 12% of the 
animals, even though almost 80% were infected  
the guinea pig model,with observed pathology 
following primary chlamydial infectionsand anatomy, 
and physiology similar to the human female genital 
tract, more closely resembles human chlamydial 
disease than them urine. 
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Vaccina0tion  against Chlamydia Genital 
Infection Utilizing the Murine C. 
muridarum Model 
The murine model of C. muridarum genital infection has been 
extremely useful for identification of protective immune 
responses and in vaccine development. Although a number of 
immunogenic antigens have been assessed for their ability to 
induce protection, the majority of studies have utilized the 
whole organism, the major outer membrane 
protein (MOMP), or the chlamydial protease-
like activity factor (CPAF). These antigens, alone and 
in combination with a variety of immunostimulatory adjuvants, 
have induced various levels of protection against infectious 
challenge, ranging from minimal to nearly sterilizing 
immunity.  9 By: Mehri Sadeghi /                                          
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Whole Organism Vaccines— 
First-Generation C. trachomatis Vaccines 
Initial attempts to develop an effective vaccine for 
controlling both animal and human chlamydial 
infections began with the use of inactivated or live, 
attenuated whole organism preparations in the 1950s. 
These vaccines can offer a degree of protection but 
are far from ideal. Common problems are the cost 
and the complexity of production, the 
requirement for cold storage, the presence of 
antigens which can induce autoimmunity or 
immunopathology, and the limited efficacy in 
neonates with high levels of maternal 
antibodies 
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Live Attenuated Organisms 
The first vaccines that were used against Chlamydiaceae were 
live vaccines. With this method of immunization, attenuated or 
modified living chlamydial organisms were used. The 
development of attenuated strains usually happens by a number 
of passages of the wild-type strain in different types of cell 
cultures or by chemical mutagenesis. Due to the passages, one 
or more mutations could arise, resulting in a nonvirulent 
attenuated strain. Live attenuated vaccines can elicit humoral 
and cellular immunity, because they replicate in a manner 
analogous to the target pathogen, promoting the processing and 
presentation of antigens in a way that is most similar to the 
natural infection.  
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On the other hand, they can also revert to the virulent wild-
type strain resulting in disease or persistent infection. 
Whole-organism vaccination is unlikely to be attempted in 
the near future, because there is a risk of immunopathology, 
the large-scale production of pure chlamydiae is extremely 
difficult and because of the possible spread of 
live Chlamydiaceae in the environment 
In view of the safety aspects (possible return to the 
virulent wild type strain) and the risk for 
immunopathological damage, it seems unlikely that a live 
attenuated C. trachomatis vaccine will be allowed in 
humans. 
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Inactivated or Killed Organisms 
Because live vaccines are not always safe or 
available, research switched to the use of killed or 
inactivated organisms. Inactivation was done by 
heat or chemical treatment.  
Their major disadvantage is that they are not able to 
replicate anymore, which stresses the need to 
revaccinate and to use adjuvants. Another 
consequence of their inability to replicate is that they 
are poor inducers of cell-mediated immunity although 
they can induce and adequate level of humoral 
immunity. Because a strong cell-mediated immunity is 
needed for clearance of chlamydial infections, 
inactivated or killed organisms seem to be less 
suitable for vaccine development 
against Chlamydiaceae 
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In this study, Peterson et al failed to elicit a 
protective response to a vaginal C. 
trachomatis infection in mice immunized 
intranasally and intraperitoneally with 1 × 106 UV 
inactivated inclusion forming units of C. 
trachomatis serovar E. 
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 Subunit Vaccines—Second-Generation C. 
trachomatis Vaccines 
Vaccine candidate antigens, or parts of antigens, 
may be represented as purified proteins, 
recombinant proteins or as synthetic proteins . 
 
But subunit vaccines have also some 
disadvantages. Like inactivated vaccines, 
 
they are poor inducers of cell-mediated immunity, 
which is very important in the defense against 
chlamydial infections. Further more, the use of 
adjuvants is being recommended. 
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Purified MOMP and COMC Preparations 
vaccine research mainly focused on this protein. Some 
results were encouraging while others rather disappointing. 
Pal et al,found that a chlamydial outer membrane complex 
(COMC) preparation of C. muridarum could induce 
significantly protective immunity in mice against a genital 
challenge, while purified MOMP preparations could not. 
 
 Some years later, the same research group immunized mice 
with a purified and refolded preparation of the C. 
muridarum MOMP in combination with Freund’s adjuvants.  
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Igietseme and Murdin ,prepared a MOMP-ISCOM vaccine 
based on MOMP extracted from C. Trachomatis serovar D. 
This vaccine was able to produce a Th1 antigen-specific 
immune response, and immunized mice cleared a vaginal 
infection within one week. 
From these studies, it is clear that some preparations can 
induce more protection than others. This is probably due 
to the difference in extraction method which can influence 
the preservation of conformational MOMP epitopes, 
necessary for protection. Although vaccination with 
refolded, purified MOMP preparations have been 
reasonable successful, the major drawbacks of these 
vaccines are that they are very expensive and there are 
problems to grow chlamydia in bulk, which renders these 
kinds of vaccines commercially non-viable. 
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Recombinant Proteins 
Systemic immunization of mice with rMOMP from C. 
trachomatis could reduce the number of animals 
developing severe salpingitis but failed to reduce 
chlamydial colonization of the lower genital tract. Mice, 
immunized with rMOMP directly into the Peyer’s patches 
(to stimulate mucosal immunity), shed fewer chlamydiae 
from the vagina, but showed little reduction in oviduct 
damage. Furthermore, the number of animals developing 
severe salpingitis could not be reduced. Although in 
both cases specific IgG and IgA antibody responses 
could be observed, they could not completely protect 
the mice. 
For chlamydial vaccines, recombinant MOMP 
(rMOMP) is generally used.  
By: Mehri Sadeghi /                                          
Dr. M.Aslanimehr 
19 
Synthetic Peptides 
Studies with MOMP peptides and oligopeptide vaccines 
showed variable results with maximum partial 
protection. Preliminary studies in mice indicated that 
intradermal injection of a peptide from a conserved 
region of the MOMP of C. trachomatis, conferred some 
protection against the development of salpingitis .In 
contrast to these findings, Su et al. found that parenteral 
immunization of mice with an alum-adsorbed synthetic 
oligopeptide of the C. trachomatis MOMP, was 
ineffective in preventing chlamydial genital tract 
infection although mice produced high levels of 
antichlamydial serum IgG neutralizing antibodies.. 
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Therefore, DNA vaccination which 
induces both humoral and cellular 
immune responses can be an 
alternative method to protect animals 
from chlamydial infections 
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DNA Vaccines—Third-Generation C. 
trachomatis Vaccines 
The first attempt to generate an MOMP-based DNA 
vaccine against a genital chlamydial challenge was 
disappointing . 
This vaccine encoded the MOMP gene of C. muridarum. Only 
modest immune response was elicited, but no protection 
could be established against infection or disease.  
In 2010 and 2011, Schautteet et al. studied the ability of 
a DNA vaccine based on C. trachomatis MOMP to 
protect against genital C. trachomatis infection in a 
recently developed pig model .When administrating 
the vaccine to the vaginal mucosa, a cellular immune 
response was induced which elicited significant 
protection in pigs. The infection could not be cleared 
completely [ 
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In 2008, a pORF5 DNA vaccine was evaluated for 
its protective immunity in a mouse model of 
genital chlamydial infection. The vaccinated mice 
displayed significantly reduced bacterial 
shedding upon chlamydial challenge and an 
accelerated resolution of the infection. 
Furthermore, the immunized mice also exhibited 
protection against pathological consequences of 
chlamydial infection. These results demonstrate 
the potential of the pORF5 DNA vaccine to elicit 
protective immunity against a genital chlamydial 
challenge  
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Poly(lactic acid)–poly(ethylene glycol) 
nanoparticles provide sustained 
delivery of a Chlamydia trachomatis 
recombinant MOMP peptide and 
potentiate systemic adaptive immune 
responses in mice 
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Thank  you  
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